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Parkinson’s disease (PD) is one of the neurodegenerative diseases which we can by certainty identify its pathology, however, this
conﬁdencedisappeareswhentalkingaboutthecause.Alonghistoryoftrials,suggestions,andtheoriestriedlinkingPDtoaspeciﬁc
causation. In this paper, a new suggestion is trying to ﬁnd its way, could it be toxicology? Can we—in the future—look to PD as an
occupational disease, in fact, many clues point to the possible toxic responsibility—either total or partial—in causing this disease.
Searching for possible toxic causes for PD would help in designing perfect toxic models in animals.
1.Introduction
The term “Parkinson’s disease” refers to a neurodegenerative
disease that aﬀects several regions of the brain, including the
pigmented nuclei in midbrain and brainstem, the olfactory
tubercle, the cerebral cortex, and elements of the peripheral
nervous system [1].
2. HistoricalBackground
Parkinson’sdiseasewasﬁrstdescribedinamedicalcontextin
1817byJamesParkinson,ageneralpractitionerinLondonin
his Essay on the Shaking Palsy [2].
Even earlier many physicians have picked up some of the
features of Parkinson’s disease and described them in their
writings, for example, Franciscus de le B¨ oe (1614–1672) who
d e s c r i b e dt r e m o r sa n dF r a n c ¸ois Boissier de Sauvages de la
Croix (1706–1767) who described patients with “running
disturbances of the limbs.”
Wilhelm von Humboldt (1767–1835), the celebrated
academic reformer and writer who lived in the era of
Parkinson, has described his own neurological condition in a
series of letters [3].
2.1. PD Is a Signiﬁcant Clinical Problem. PD represents
a major clinical problem. Reviewing the multiple clinical
ﬁndings in PD will show us the need of more researches to
reach a possible curative therapy [4].
A group of neurobehavioral abnormalities can be found
in PD such as apathy, fearfulness, anxiety, emotional lia-
bility, social withdrawal, increasing dependency, depres-
s i o n ,d e m e n t i a ,b r a d y p h r e n i a ,at y p eo fa n o m i at e r m e d
the “tip-of-the-tongue phenomenon,” visual-spatial impair-
ment, sleep disturbance, psychosis, and other psychiatric
problems [5].
The variable presentations of PD often cause diagnostic
confusion and a delay in treatment. In the early stages,
Parkinsonian symptoms are often mistaken for simple
arthritis or bursitis, depression, normal aging, Alzheimer’s
disease,orstroke.Goneraetal.[6]characterizedaprodromal
phase 4–6 years before the main manifestation in PD
patients. During this period, PD patients, compared with
normal controls, had a higher frequency of mood disorder,
“ﬁbromyalgia,” and shoulder pain.
A sum of possible PD manifestations would be tremorsat
rest, rigidity, bradykinesia, and loss of postural reﬂexes which
represents the cardinal manifestations besides possibility of
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(i) Hypomimia (masked facies).
(ii) Speech disturbance (hypokinetic dysarthria).
(iii) Hypophonia.
(iv) Dysphagia.
(v) Sialorrhea.
(vi) Respiratory diﬃculties.
(vii) Loss of associated movements.
(viii) Shuﬄing, short-step gait.
(ix) Festination.
(x) Freezing.
(xi) Micrographia.
(xii) Diﬃculty turning in bed.
(xiii) Slowness in activities of daily living.
(xiv) Stooped posture, kyphosis, and scoliosis.
(xv) Dystonia, myoclonus, orofacial dyskinesia.
(xvi) Neuro-ophthalmologic ﬁndings.
(xvii) Impaired visual contrast sensitivity.
(xviii) Visuospatial impairment.
(xix) Impaired upward gaze, convergence, and smooth
pursuit.
(xx) Impaired vestibuloocular reﬂex.
(xxi) Hypometric saccades.
(xxii) Decreased blink rate.
(xxiii) Spontaneous and reﬂex blepharospasm (glabellar or
Myerson’s sign).
(xxiv) Lid apraxia (opening or closure).
(xxv) Motor ﬁndings related to dopaminergic therapy.
(xxvi) Levodopa-induced dyskinesia (chorea, dystonia, my-
oclonus, tic) [7].
2.2. Neuropathology. Parkinsonism results primarily from
abnormalities of basal ganglia function. The basal ganglia
include the neostriatum (caudate nucleus and putamen)
the external and internal pallidal segments (GPe, GPi), the
subthalamic nucleus (STN), and the substantia nigra with its
pars reticulata (SNr) and pars compacta (SNc) [1].
They participate in anatomically and functionally segre-
gated loops that involve speciﬁc thalamic and cortical areas
[8].
Striatum and STN receive glutamatergic aﬀerents from
speciﬁc areas of the cerebral cortex or thalamus, and transfer
the information to the basal ganglia output nuclei, GPi and
SNr [1].
The striatum also receives prominent dopaminergic
input, from the SNc. The nigrostriatal projection terminates
predominately at the necks of dendritic spines of the striatal
medium spiny output neurons (MSNs). MSN spines also
receive corticostriatal terminations. This anatomic arrange-
mentplacesthedopaminergicinputsinapositiontoregulate
or gate the corticostriatal transmission [9].
In Parkinson’s disease, the degeneration of dopaminergic
SNc neurons and their projections to the striatum is a slowly
evolving process that may take decades to develop [10].
SNc projections to the putamen degenerate earlier than
projections to associative or limbic portions of the striatum.
Corresponding to this time course of degeneration, the
motor symptoms and signs of Parkinson’s disease develop
before the nonmotor signs. Recognizable motor or non-
motor signs appear only after substantial degeneration
of the nigrostriatal neurons (aﬀecting at least 70%), this
is due to the remarkable compensatory capacity within
the dopaminergic system, or in the circuits it modulates
[1].
The most frequent pathologic substrate for PD is Lewy
body disease. The brain is usually grossly normal when
viewed from the outer surface. There may be mild frontal
a t r o p h yi ss o m ec a s e s ,b u tt h i si sv a r i a b l e .
Histologically, there is neuronal loss in the substantia
nigra pars compacta along with compensatory astrocytic and
microglial proliferation. Although biochemically there is loss
of dopaminergic termini in the striatum, the striatum is
histologically unremarkable [11].
Hyaline cytoplasmic inclusions or Lewy bodies and less
well-deﬁned “pale bodies” are found in some of the residual
neurons in the substantia nigra [10].
Lewy bodies are proteinaceous neuronal cytoplasmic
inclusions [12]. In some regions of the brain, such as the
dorsal motor nucleus of the vagus, Lewy bodies tend to form
within neuronal processes and are sometimes referred to as
intraneuritic Lewy bodies. In most cases, Lewy bodies are
accompanied by a variable number of abnormal neuritic
proﬁles, referred to as Lewy neurites.
Lewy neurites were ﬁrst described in the hippocam-
pus [13], but are also found in other regions of the
brain, including theamygdala,cingulate gyrus,andtemporal
cortex.
At the electron microscopic level, Lewy bodies are com-
posedofdenselyaggregatedﬁlaments[14]andLewyneurites
also are ﬁlamentous, but they are usually not as densely
packed [13].
Some authors suggested that pre-Parkinsonian manifes-
tations would be nonmotor (e.g., autonomic dysfunction
andanosmia)andthatthelatestagewouldbeassociatedwith
cortical Lewy body dementia [15].
2.3. Pathogenesis
2.3.1. Δ  ψα-Synuclein: “The Culprit in Parkinson’s Dis-
ease?” [2]. Synuclein has gain interest for its role in PD
neurodegeneration since the demonstration that α-synuclein
is the major component of Lewy bodies and Lewy neuritis in
idiopathic PD [16].
The exact mechanisms of how conformational changes
of α-synuclein induce cell death are currently the sub-
ject of intense investigation, but are still poorly under-
stood. It has been suggested that α-synuclein oligomers
might form pores on intracellular membranes such as the
plasma membrane, and may increase cation permeability
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α-Synuclein has been reported to negatively regulate
the activity of tyrosine hydroxylase by maintaining the
protein in the dephosphorylated inactive form, thus modu-
lating dopamine biosynthesis in catecholaminergic neurons
[17].
In addition, α-synuclein was proposed to negatively reg-
ulate the function of the dopamine transporter in dopamin-
ergic nerve terminals by controlling the amount of the
transporter at the plasma membrane [18].
2.3.2. Tau in PD. Tau is a microtubule-binding protein that
stabilizesmicrotubulesandpromotestheirpolymerizationin
neurons. Six isoforms of tau are present in the adult human
brain [19].
While PD is the best known of the α-synucleinopathies,
tau pathology is also seen in many PD cases. staining of
Lewy bodies with multiple tau antibodies has been reported,
suggesting cellular colocalization of these two pathologies
[20].
2.3.3. Parkin, UCHL1, α-Synuclein, and the Ubiquitin-Pro-
teasome Pathway: “Pieces of a Puzzle?” [2]. Both of the
proteins (UCHL1 and parkin) are involved in the ubiquitin-
proteasome pathway of abnormal protein degradation which
is considered to be a cellular quality control [21].
When this pathway is impaired, disease can result. Thus,
it is possible that mutations in the parkin and UCHL1 genes
may lead to malfunction of the pathway [22] and damaged
proteins are not degraded. Instead, they form aggregates
that ultimately lead to cell degeneration with an unknown
mechanism [23].
2.3.4. Mitochondrial Dysfunction in PD. The direct relation
between mitochondrial dysfunction and PD came from
the postmortem description of complex I deﬁciency in the
substantia nigra of patients with PD. Subsequently, the
deﬁciency was also seen in the skeletal muscle and platelets
and there was a decrease in complex I proteins in the
substantia nigra of patients with PD [24].
Dopaminergic (DA) neurons are particularly prone to
oxidative stress. DA metabolism and auto-oxidation com-
bined with increased iron, decreased total glutathione levels,
andmitochondrialcomplexIinhibitioncanleadtocelldeath
by exceeding the oxidative capacity of DA-containing cells in
the region [25].
2.3.5. Calcium Homeostasis and Excitotoxicity. It has been
an attractive hypothesis for decades that excitotoxicity and
disturbance in calcium homeostasis are mechanisms leading
to neurodegeneration; disturbed calcium homeostasis is
done through the activation of calpains, a family of cysteine
proteases [16].
These are elevated in the mesencephalon of patients with
PD but not in other neurodegenerative disorders involving
the mesencephalon. David Park and colleagues have shown
that calpains are activated and required for MPTP-induced
neuronal death in mice [26].
2.4. Toxic Parkinsonism, Why? “In one of his Dialogues,
the Greek philosopher Plato speculated that our minds
contain a block of wax, the size, hardness, and consistency
of which varies from person to person. Everything we think
or perceive leaves an impression on the wax, and the quality
and duration of this impression is the basis of our memory
and knowledge.” This metaphor was used by Di Monte [27],
to describe the relation between genetics and environmental
risk factors in developing PD.
PD is considered a multifactorial disease resulting from
the eﬀect of environmental factors and genetic susceptibility.
Linking PD to an environmental cause, however, seems
diﬃcult. This is because of the long presymptomatic period
[28].
Despite the mysterious cause of PD, the pathologic and
neurochemical basis of parkinsonian signs and symptoms
have been in part unraveled as discussed earlier. Toxic insults
could both modify the structure of α-synuclein and interfere
with the ubiquitin-proteasomal pathway, thus, promoting α-
synuclein aggregation and impairing the process of degrada-
tion of the abnormal protein [29].
Barlow et al. [30] found that even in utero exposure
with subsequent genetic damage can be a risk factor for
neurodegenerative diseases, for example, Alzheimer and PD.
This can explain the ﬁnding of Tsai et al. [31] who described
what he has called a young onset parkinsonian disease
(YOPD) which is a peculiar group of patients developing PD
before 40 years on contrary to normal age group of more
than 50 years.
The reason for trying to identify toxic causes of PD
(besides future protection) is the search for a perfect PD
model. Scientists are trying to unravel the exact cause of PD;
also we are trying to ﬁnd out a perfect therapy and both the
therapy and cause need a perfect model to act on. Finding a
toxinthatcanbeatruecauseofPDwouldsolvetheproblem.
So, what are those toxins that can be candidates for
toxic PD models? Many have been described including the
following.
2.4.1. Pesticides. Many risk factors have been implicated in
PD. Since the discovery of MPTP, parkinsonian inducing
eﬀects this arouse the possibility of other similar compounds
relevant to MPTP, for example, paraquat to induce PD [32].
Numerous classes of pesticides were introduced during
the twentieth century. Although PD existed long before the
introduction of these pesticides, the thought is that pesticide
exposure has contributed to the increased incidence of the
disease [33].
2.4.1.1.Fumigants. Thefumigantclassencompassesavariety
of agents most commonly used to control insects or fungi
in grains, soil, or other various consumables. Fumigants,
such as ethylene dibromide, are highly toxic to humans but
most adverse actions are nonneuronal [34]. Although there
is some evidence that carbon disulﬁde-based fumigants can
induce parkinsonian-like neurotoxicity [35]. This chemical
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2.4.1.2. Fungicides. Fungicides are agents of a wide variety
of chemical structures. Maneb, or manganese ethylene bis-
dithiocarbamate, is one type with possible parkinsonian
symptoms which may be secondary to exposure to the
manganese metal core [33].
In fact, maneb is one of the toxins used to induce PD
in animal models but usually in combination with other
agents specially paraquat [36]. The maneb eﬀect has been
undoubtedly documented to increase the severity of PD
models which make it one of the good candidates in PD
research [37].
2.4.1.3. Herbicides (Paraquat). The possibility that paraquat
(1,1 -dimethyl-4,4 -bipyridinium) may damage the nigros-
triatal dopaminergic system and therefore contribute to
the neuropathology of Parkinson’s disease (PD) was ﬁrst
proposed in the mid 1980s following the observation that its
chemicalstructurecloselyresemblesthatofMPP+(1-methyl-
4-phenylpyridinium ion) [38].
Animal studies conﬁrmed the ability of paraquat to in-
duce selective dopaminergic nigrostriatal degeneration [39–
41].
Lietal.[40]havedevelopedsubacutemodelforinducing
PD in mice through using intraperitoneal injection of
paraquat (10mg/kg) in old C57/bl mice. Similar results were
obtained 2 years later by Kuter et al. [41] using a similar
approach.
As described earlier, an improvement in modeling of
paraquat induced PD was through adding maneb. A com-
bination which improved the results. It also supported the
multiple hit theory of PD [42].
The presence of diﬀerences between paraquat and MPTP
has been questioned and the answer would come from a
group of articles in Toxicological Sciences journal regarding
mechanism of paraquat toxicity. Richardson et al. [43]
proposedthatparaquatwouldhavediﬀerentmechanismsfor
toxicity than MPTP. Later, Ramachandiran et al. [44]h a v e
shown that paraquat and MPTP have divergent mechanisms
of toxicity. Another hot debate emerged on the same
journal regarding the possibility of diﬀerent mechanisms of
neurotoxicity between paraquat and MPTP [45–48].
Despite the debate, there are certainly toxicokinetic
and toxicodynamic diﬀerences which would give paraquat
a unique pattern of neurotoxicity. Despite the fact that
paraquat models are still less validated than the previous
well-established MPTP models [49], combining maneb with
paraquat would introduce a promising modeling technique
that can be (in our opinion) a better model specially with the
limitation in the other available toxic models.
2.4.1.4. Insecticides. There are several subclasses of insecti-
cides, each with their own subdivisions. Many of the com-
pounds in this class are, by design, neurotoxic. Similarities
between the insect and human nervous systems can lead to
cross-toxicity of these compounds [33].
2.4.1.4a. Organophosphates. Although evidence supporting
a role for OPs in PD pathogenesis is scant, there are
case reports of people with severe Parkinsonism after OP
exposure [50]; however, the reversibility of the symptoms
and lack of responsiveness to L-dopa are not consistent with
PD. A recent family-based case-control study did implicate
organophosphates and other insecticides in PD [51].
However, it might be that the eﬀects of OP exposure
probably involve disturbance of the balance between the
dopamine and acetylcholine systems and not speciﬁc patho-
logical changes in the dopamine system which makes them
unsuitable in toxic modeling of PD [52].
2.4.1.4b. Rotenone. Due to its ability of inhibiting mito-
chondrial complex I (NADH dehydrogenase), rotenone has
become one of the toxic models used to study PD in animals
[33, 53].
Chronicsystemicexposuretorotenonereproducedmany
features of PD, including nigrostriatal dopaminergic degen-
eration and the formation of cytoplasmic inclusions in these
neurons. Rats exposed to rotenone showed bradykinesia,
postural instability, unsteady gait, and some evidence of
tremors [54, 55].
Recently, Cannon et al. [56]r e p o r t e da ni m p r o v e d
rotenone model through giving 3mg/kg daily with observa-
tion of behavioral changes including bradykinesia, postural
instability/unsteady gait, and rigidity, which occurred max-
imally after 6 days of treatment where postmortem analysis
(immunohistochemistry of the TH+ve neurons in substantia
nigra) conﬁrmed the behavioral observations. Others have
shown the eﬃcacy of rotenone as a model of PD in mice
and suggested its use for assessing candidate anti-Parkinson
drugs [57].
Rotenone model can be used as an alternative to other
classical PD models, for example, MPTP and 6-OHDA,
especially when testing the neuroprotective eﬀects of novel
therapeutic modalities [58]. A limiting factor of rotenone
modelswouldbethehighmortalityrateoftheexaminedani-
mals. Another limitation would be the less-accurate results
that can be obtained usually in cases of oral administered
rotenone [59].
2.4.1.4c.Organochlorines. Theﬁrstclueofarelationbetween
organochlorines and PD was the presence of them in
postmortem specimens of PD patients [33]. Kanthasamy
et al. [60] have postulated possible mechanisms for the
inﬂuence of organochlorines on PD patients.
2.4.1.4c.i. Eﬀects on Dopamine and Dopamine Trans-
porters. The assumption that organochlorines deplete brain
dopamine was supported by the ﬁndings of Miller et al. [61].
They measured the expression and activity of the dopamine
transporter (DAT) and the vesicular monoamine transporter
(VMAT2) in presynaptic terminals of dopaminergic neurons
in the striatum. Exposure of C57BL mice to an organochlo-
rine pesticide (increased the expression of both DAT and
VMAT2 in the striatum).
Sanchez-Ramos et al. [62] showed that dieldrin is selec-
tively toxic to dopaminergic neurons compared to striatal
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2.4.1.4c.ii. Dieldrin-Induced Oxidative Stress. Dieldrin expo-
sure was shown to induce ROS production in a number of
cell culture models including neuronal cell lines, mouse lung
ﬁbroblasts, and in mouse liver [63, 64].
Chun et al. [63] showed that dieldrin exposure induces
ROS production in a mouse nigral dopaminergic cell line.
2.4.1.4c.iii. Dieldrin and Mitochondrial Dysfunction. Dield-
rin exposure has been shown to alter mitochondrial function
and induce the release of cytochrome c in a human T cell
leukemic cell line [64].
Neuronal death in PD seems to be mitochondrial
dependent. Through oxidative mechanisms the soluble pool
of cytochrome C in the mitochondrial intermembrane space
is increased. For the release of cytochrome C into the cytosol,
an activation of Bax to permeabilize the outer mitochondrial
membrane appears to be necessary [60].
2.4.1.4c.iv. Eﬀects on Caspases. Activation of caspases is an
essential step in the apoptotic signaling pathway. Recently
caspase 3 has been identiﬁed as a critical factor in apoptotic
cell death in dopaminergic neurons [65].
PKCd is an important apoptotic substrate for caspase-3,
and subsequent studies have implicated caspase-3-mediated
p r o t e o l y t i ca c t i v a t i o no fP K C di na p o p t o t i cc e l ld e a t h[ 66–
69].
Dieldrin treatment induced dose and time-dependent
proteolytic cleavage of native PKCd (72 and 74kDa) into two
fragments, 38kDa regulatory and 41kDa catalytic subunits,
in dopaminergic cells [70, 71].
2.4.1.4c.v. Eﬀects of Dieldrin on α-Synuclein Aggregation
and Ubiquitin-Proteasome Function. Sun et al. [72] ﬁndings
suggest that dieldrin can alter the function of the ubiquitin-
proteasomal degradation machinery to promote protein
aggregation.
These encouraging data would increase the organochlo-
rines chance of being a new toxic PD model, especially with
their potential of accumulation and so chronic exposure
which is one of the characteristics needed to reproduce the
exact pathological ﬁndings in animal PD models.
2.4.1.4d. Pyrethroids. Although pyrethroids are often con-
sidered environmentally labile, exposure of mice to the
pyrethroid pesticides deltamethrin and permethrin has been
demonstrated to increase DAT-mediated dopamine uptake
[73–75]. Acute toxicity of pyrethroids is primarily mediated
through interaction with sodium channels, leading to pro-
longed depolarization and hyperexcitation of the nervous
system [76].
Pyrethroids have also been shown to be potent releasers
of neurotransmitters, including dopamine [73].
Although the mechanism by which pyrethroids are
capable of increasing DAT-mediated dopamine uptake is not
clear, Elwan et al. [77] suggest that the eﬀects of pyrethroids
on DAT are indirect and that longer-term exposures may be
capable of damaging cells through an apoptotic mechanism.
The use of pyrethroids in modeling of PD is still far from
validation as frequent researches are needed to reach a ﬁnal
exposure protocol.
2.4.1.5. Metals. T h eﬁ e l do fm e t a l si nn e u r o s c i e n c eh a s
expanded extraordinarily. The biometals, iron, copper, zinc,
and manganese participate in many essential activities, and
indeed deﬁciencies can be lethal. Zinc and iron are increased
and copper is decreased in the substantia nigra (SN) in
Parkinson’s disease (PD) [78].
2.4.1.5a. Iron and PD. Of great interest is the possible
association between iron and nigral melanin as a source of
free radicals. Also, iron is postulated to interact with DA
or derived catecholic chrome derivatives discussed above,
speciﬁcally by reacting with hydrogen peroxide that can be
generated to produce short-lived hydroxyl radicals [79].
Searches for the mutation of genes associated with
iron metabolism have revealed mutations in the ferritin-H,
IRP2, and HFE gene in single PD patients. Ceruloplasmin
mutations causing protein instability and loss-of-function
lead to extrapyramidal symptoms and Parkinsonism, and are
characterized by iron accumulation in the substantia nigra
[78].
2.4.1.5b. Manganese: Nontypical PD Manifestations. Man-
ganese is an essential metal for life, yet chronic exposure
to this metal can cause a neurodegenerative disease named
manganism. Despite similar clinical pictures, in Parkinson’s
disease the domaninergic neurons in the substancia nigra
are damaged, while in manganism, Mn accumulates in the
globus pallidus and striatum, and it damages these two
brain structures that control motor function [80]. So despite
having some similar manifestations, Mn cannot be ranked as
one of the causes of PD.
2.4.1.5c. Metals and α-Synuclein. Uversky et al. [81]h a v e
shown that some metal ions can induce α-synuclein ﬁbril-
lation (impaired metabolism of normal α-synuclein, known to
accumulate massively in Lewy bodies (LBs), is considered the
primary cause of neurodegeneration in idiopathic PD). The
most eﬀective ions were Al
3,F e 3,C o 3,C d
2,M n 2,C u 2,C o 2,
in that order. Moreover, they found that combination of
metals and pesticides have synergistic eﬀects on α-synuclein
ﬁbrillation.
The use of metals in toxic animal models however is
diﬃcult and did not gain any popularity due to diﬃculties
in application and assessment.
2.4.1.6. Drug Abuse and PD
2.4.1.6a. Amphetamines. Abuse of amphetamine derivatives
is a growing phenomenon in the Western World. Both MA
and its derivative, 3,4-methylenedioxymethamphetamine
(MDMA, “ecstasy”), are known to be toxic for dopamine
nerve terminals, thus replicating striatal DA loss occurring
in Parkinsonism. It has been shown that MA and MDMA6 Neurology Research International
induce neuronal inclusions in the substantia nigra and
corpus striatum of mice [82].
However, in case of drug-induced PD, it is important
to interpret neuronal damage—using markers—cautiously
as there are usually compensatory changes in these enzymes
which may not reﬂect neurodegeneration [83].
Amphetamine and its derivatives may be applied as toxic
models for PD. They are similar to MPTP with safer proﬁle.
2.4.1.6b. MPTP. The potent parkinsonian neurotoxin, 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes
PD in animals and is one of the most accepted models. This
may be due to its capacity to show some of PD pathological
ﬁndings (SN neuron loss and striatal DA depletion similar to
PD) [84].
MPTP-treated animals (including humans) do not
exhibit Lewy bodies (LB), a hallmark neuronal inclusion
of PD, but old treated primates have inclusions that are
somewhat similar. Humans and many other animal species
including nonhuman primates, guinea pigs, mice, and cats
are susceptible to this neurotoxin [85].
One interesting feature of the MPTP mouse model of PD
is the transient nature of the striatal damage in young mice.
In contrast, administration of the drug to older mice would
result in a permanent loss of nigrostriatal terminals, as well
as cell bodies. This recovery potential in young mice allows
for modeling of recovery [84].
Various techniques can be used to modulate the action of
MPTP to induce the pathological ﬁndings needed to reach
the desired PD model. One of these techniques is to give
probenecid with MPTP to prolong its persistence in the
tissues [86].
In sporadic PD, the generation of neural precursor cells
in the subependymal zone is impaired by DA depletion,
which is the hallmark of PD. MPTP-induced degeneration
of dopaminergic SNpc-SVZ ﬁbres impairs NSC proliferation
in primates and in mice in a similar fashion to PD [87]. He
et al. [88] raised the possibility that migrating neuroblasts
in the SVZ may be more vulnerable to MPTP than nigros-
triatal dopaminergic neurons in the SN. Furthermore, they
suggested that the death and subsequent loss of migrating
neuroblasts in the acute or subacute model probably lead to
a decreased potential for neurogenesis to some extent.
Several MPTP dosing regimens have been used. The
acute regimen consists of multiple systemic administration
of MPTP (usually four doses at 2-h intervals per day). The
subacuteregimenconsistsofasinglesystemicadministration
per day for several consecutive days (usually 5 days) and the
chronic regimen through several weeks [89].
The comparison of these diﬀerent models indicated
clearly that diﬀerent schedules of administration of MPTP
mimic distinct stages of the disease and might induce
diﬀerent mechanisms of neuronal death [90].
One of the limitations of MPTP models is their inability
to induce behavioral deﬁcits apparent on standard motor
mouse tests. However, new techniques for behavioral mon-
itoring have shown promising results, for example, Grid test
[84] and its modiﬁcation, the vertical grid test and modiﬁed
horizontal grid test [91], swim test [85], or the automated
behavioural apparatus, LABORASTM (Laboratory Animal
Behaviour Observation, Registration and Analysis System)
[92].
Strain diﬀerences regarding the response to MPTP has
been questioned where C57/bl mice show maximum
response compared to BALB/c mice [85, 93, 94]. This does
not contradict the old results of Hu et al. [95], who found
prominent changes in BALB/c response to MPTP as BALB/c
mice still show a possible alternative, though less eﬀective to
C57/bl.
AnimportantpropertyoftheMPTP-lesionedmouseand
nonhuman primate is the potential for intrinsic recovery.
This capacity would be of great help in identifying new
therapeutic targets for the treatment of PD [96].
3.Environment,Genetics,andPD
PD is a multifactorial disease, so despite role of environ-
mental exposure, genetic predisposition in sporadic cases
can be broadly grouped into four categories: genes involved
in the metabolism of xenobiotics (e.g., CYP2D6, NAT2,
GSTs), neurodegeneration (e.g., NOS), the functioning of
dopaminergic neurons (e.g., dopamine transporters and
receptors), and linkage-derived genes (e.g., UCHL1, alpha-
synuclein) [97].
There is increasing evidence that genes involved in
inheritedformsofthediseasemayactaspredisposing factors
in the sporadic forms of PD. So, new models of PD produced
in vivo on transgenic animals and in vitro on transfected
cell cultures are considered important because they may be
helpful in discovering the pathophysiology of PD [98].
M e r e d i t he ta l .[ 89] have classiﬁed genetic models into
threecategories.First,mousemodelsbasedonthedeletionof
genes important for the development or maintenance of DA
neurons or their phenotypes. Second, mouse or rat models
based on expression or deletion of genes known to cause
familial forms of PD. Finally, a third class of genetic models
isbasedonvirallymediatedexpressionofgenesormutations
known to cause familial PD, usually in nigrostriatal DA
neurons.
Despite having some features of the human disease,
genetic models do not provide an ideal choice for assessing
regenerating capacity of new therapeutic approaches and so
are of less use for pharmaceutical development [99].
4. Conclusion
In our search for an ideal toxic model of PD, we could not
ﬁnd a perfect one. It seems that all toxins when used alone
canprecipitateonlysomecharactersofPDpathologybutnot
the exact PD condition.
These same ﬁndings may be the cause of the Manning-
Bog and Langston [100] advice of using model fusion to
overcome the single model limitation through combining
genetic with toxic models. We would encourage the use of
toxins combination in PD modeling as a new type of model
fusion.Neurology Research International 7
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